Key snapshot of Dynavax Technologies

Dynavax Technologies (DVAX) has drawn investor attention recently as its shares trade around $15.49, with returns roughly flat over the past month and a gain over the past 3 months.

The commercial stage vaccine maker reports annual revenue of about US$330.514 million and a net loss of roughly US$43.401 million, giving investors a mix of established product sales and ongoing investment in its pipeline.

While the share price return over the past year has been relatively modest compared with some peers, the 90 day share price return of 54.13% suggests momentum has recently picked up as investors reassess Dynavax Technologies' risk and growth profile, supported by a 1 year total shareholder return of 19.71%.

If Dynavax's recent move has you thinking about other healthcare names, it could be a good moment to see what stands out among healthcare stocks.

With Dynavax trading around $15.49, sitting on a 54.13% 90 day share price return and a loss of about US$43.401 million against revenue of roughly US$330.514 million, is there still a potential opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 19.5% Undervalued

At $15.49, the most followed narrative places Dynavax Technologies' fair value at $19.25, creating a gap that depends on how its vaccine portfolio and earnings potential develop.

Ongoing investment in the development pipeline (notably the shingles, pandemic influenza, and Lyme disease vaccine programs) positions Dynavax to benefit from heightened global government/public health focus on pandemic preparedness and preventative care, creating new long-term revenue streams and diversifying future earnings.

Curious what would have to happen for that valuation to align? Revenue increasing at a healthy pace, margins turning firmly positive, and a future earnings multiple that reflects durable performance. The full narrative outlines how those elements are expected to come together.

Result: Fair Value of $19.25 (UNDERVALUED)

However, this hinges on HEPLISAV B maintaining its momentum and the pipeline delivering on timelines, while partnerships, pricing pressure, or vaccine hesitancy could quickly challenge that story.

Build Your Own Dynavax Technologies Narrative

If you see the numbers differently, or prefer to test your own assumptions, you can build a personal Dynavax view in just a few minutes: Do it your way.

A great starting point for your Dynavax Technologies research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If you stop with just one stock, you could miss chances that fit your style even better, so use the Simply Wall St Screener to widen your watchlist intelligently.

• Spot potential long term compounders by zeroing in on these 875 undervalued stocks based on cash flows that may offer more attractive entry points based on cash flows.
• Ride powerful tech trends by focusing on these 24 AI penny stocks that are tied to real business models rather than just hype.
• Target income focused ideas with these 13 dividend stocks with yields > 3% that already offer yields above 3% before you commit fresh capital.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.